Akermin, based in St. Louis, Missouri, USA, is involved in the development of the low cost and energy efficient system for carbon dioxide separation and capture.
Its proprietary enzyme stabilisation and delivery system is based on a polymer coating approach that encapsulates the enzyme, which enables it to work as a catalyst effectively over extended periods in environments where it wouldn’t normally survive. This approach allows the company to develop economically viable and environmentally friendly CO2 solutions for multiple industrial applications.
Barry Blackwell, President & CEO, leads the company. He has more than 25 years of experience in acquisitions, corporate finance and commercial banking with two regional banks and an international financial services company. He was involved in establishing and leading energy, agribusiness, and pharmaceutical specialty finance groups in several executive management positions.
The Chief Technology Officer and VP Research is Dr. Alex Zaks, Ph.D. He has more than 20 years of experience working in the biotechnology and pharmaceutical Industries. He was the Development Fellow/Head of Chiral Technology at Schering-Plough Research Institute/Merck where he led the efforts to develop biological approaches to the synthesis of drug candidates.